SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The index is trending as investors weigh geopolitical tensions in the Middle East and rising energy costs against better-than-expected corporate earnings and economic data, while the community remains divided on whether the current market strength is sustainable or a sign of an AI-driven bubble.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending higher alongside the broader tech sector, primarily driven by strong investor reaction to blockbuster earnings and revenue guidance from Dell Technologies. While some market participants remain cautious due to rising geopolitical tensions in the Middle East and inflationary concerns from elevated oil prices, sentiment is currently buoyed by resilient semiconductor and AI-related performance.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom shares experienced significant volatility following a strong earnings report that was initially overshadowed by concerns over fourth-quarter guidance. Investor sentiment ultimately turned bullish as the company revealed aggressive long-term growth targets for its AI semiconductor business, including projected revenue of $230 billion by fiscal 2028.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares surged following better-than-expected fiscal second-quarter financial results and a raised full-year outlook, driven largely by rapid enterprise adoption of the company's AI coding assistant, CoCo. While retail sentiment remains extremely bullish with significant volume, some traders are expressing skepticism over the company's high valuation and persistent GAAP losses, leading to intense debate between those anticipating further gains and those looking to short the stock.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trading with elevated volatility as investors position for the upcoming Cybercab robotaxi launch event, weighing optimistic long-term autonomy hopes against near-term concerns over softening delivery growth in key markets like China. While some traders are anticipating a "sell-the-news" reaction, others are aggressively betting on a short squeeze or a broader breakout if the company demonstrates meaningful commercial fleet expansion.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

The stock is experiencing significant volatility following a failed Phase 3 trial for its Angelman syndrome drug, prompting management to evaluate the program and initiate cost-cutting measures. Despite the setback, traders are actively debating the company's valuation, focusing on its remaining commercial revenue streams and upcoming regulatory milestones, including a September PDUFA decision.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies shares are experiencing extreme volatility following a strong second-quarter earnings beat and an upward revision to its annual revenue outlook, with the conversation dominated by conflicting reactions to the stock's massive swings. Traders are debating whether the price action reflects a sustainable AI-infrastructure growth story or technical manipulation, with many expressing frustration over the intraday 'rug pulls' and aggressive price action.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is experiencing volatility as traders react to a combination of profit-taking following recent earnings, concerns regarding guidance, and ongoing speculation surrounding upcoming marketing events for GTA VI. While many investors remain bullish on the long-term potential of the game release, others are monitoring potential headwinds such as console availability and the impact of recent executive share sales.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

Fervo Energy is trending following a significant 396 MW power purchase agreement with Google, with the community debating whether the deal validates the company's long-term geothermal potential or if the valuation remains disconnected from current revenue and operational timelines. While some traders view the partnership as a major de-risking event and institutional-scale catalyst, others express skepticism regarding the company's lack of immediate profitability and future dilution risks.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors react to the launch of its Muse Spark 1.3 AI model, with traders debating whether this technological advancement justifies the company's massive infrastructure spending. While some view the stock as undervalued and primed for a breakout, others remain skeptical, pointing to broader economic concerns and skepticism regarding the long-term returns on Meta's AI investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics is experiencing significant buying pressure and volatility as investors look ahead to upcoming late-2026 clinical data readouts, specifically for its DM1 and FSHD programs. Traders are closely monitoring the company's recent leadership transition and the potential for a rebound in Elevidys revenue, while strong short interest continues to fuel speculation about a potential short squeeze or buyout.

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will...

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Equity

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.


KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics experienced a 34% revenue decline due to lower ELEVIDYS sales, incurred a $39 million litigation charge, and faces ongoing regulatory and commercial adoption risks for its product portfolio.

Sarepta Therapeutics achieved quarterly operating profitability, appointed a new CEO with extensive industry experience, and strengthened its financial position with a $197 million increase in cash and investment holdings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bullish Sentiment

U.S.-Iran conflict escalating

Bond yields (10-yr near 4.8%)

Inflation resurgence

Weak labor market (today's ADP miss)

What&#39;s the biggest risk to the market right now?

Stocktwits

What's the biggest risk to the market right now?

Stocktwits Polls

Traders are closely watching for potential signs of heavy short covering to spark a massive upward price breakout.

The 25 level is viewed as the primary technical hurdle, with investors eagerly monitoring if the price can finally sustain a breakout above it.

Expectation is building around upcoming research and data announcements, particularly regarding pipeline developments and specific disease programs.

Current Price	$23.21
Prev Close	$21.33
Open	$21.33
Dividend Yield	0.00%
50-Day Moving Average	$17.96
Beta	1.24
Avg. Volume	2.99M
PE Ratio	-8.01

52-Week High	$25.32
52-Week Low	$14.68
Market Capitalization	$2.25B
EPS (Annual)	-$7.13
Price to Book	1.60
Revenue Per Employee	$2.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info